Drugs / ASC618
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04676048 | Aug 2022 → Dec 2023 overdue | hemophilia A | ASC Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASC618 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04676048 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “ASC618, an AAV vector encoding B-domain deleted codon-optimized human factor VIII” NCT04676048 ↗ |
| Route | Intravenous | “ASC618 will be given as a single IV infusion” NCT04676048 ↗ |